learn RU58841
a potent but unapproved and potentially problematic topical anti-androgen
Search
forLearn
5 / 801 resultslearn phenoxyethanol
learn 18β-glycyrrhetinic acid
learn methylfolate calcium
learn dl-alpha-tocopherol
Research
5 / 1000+ resultsresearch Correction to: An evaluation of the federal adverse events reporting system data on adverse effects of 5‑alpha reductase inhibitors
The correction states that the label change for Finasteride was in 2012, leading to more reports of side effects from non-healthcare people.
research Oral Presentations: Abstracts of the Urological Society of Australia and New Zealand Annual Scientific Meeting, 25–28 February 2023, Melbourne, Australia
Urologists should monitor mental health in patients taking finasteride due to potential links to suicidal thoughts, adjusting dosage or stopping use if necessary. More research is needed to confirm if finasteride causes these thoughts.
research Entrepreneurship in Off-Label Drug Prescription: Just What the Doctor Ordered!
The conclusion is that off-label drug use can lead to important medical discoveries and improve patient care.
research A History of Drug Advertising: The Evolving Roles of Consumers and Consumer Protection
Drug advertising has greatly increased, changing consumer behavior and raising concerns about its influence on healthcare and patient protection.
research Cosmetics
The U.S. FDA regulates cosmetics for appearance purposes, but not as strictly as some other countries.
Community Join
5 / 1000+ resultscommunity 0.5mg Dutasteride promotes more “regrowth” than 5mg oral Minoxidil
Dutasteride promotes more hair regrowth than Minoxidil. Users discuss combining treatments for better results and share personal experiences with side effects.
community Publication concludes finasteride is a associated with a 60% risk of persistent sexual dysfunction.
Finasteride is not linked to a 60% risk of persistent sexual dysfunction; this figure applies only to those already experiencing sexual issues. Most users do not have side effects, and the study's methodology is criticized for selection bias.
community FDA Policy Shift Explained: What It Actually Means for PP405, VDPHL-01, Breezula and Hair Loss Drug Timelines
The FDA policy change may speed up approval for hair loss drugs like PP405, VDPHL-01, and Breezula by potentially eliminating the need for a second confirmatory Phase 3 trial. Approval timelines could be as early as 2028 for some treatments if Phase 3 results are strong.
community Discussion: Evidence Refuting the "24-Hour Rule" for Minoxidil and Dermarolling
The 24-hour waiting period after dermarolling before applying minoxidil is unnecessary. New research supports the simultaneous application of minoxidil with microneedling for better hair growth results.
community Warning: Him's fraudulently reactivated subscription and refused to refund.
Hims reactivated a subscription without consent, leading to unauthorized charges for Finasteride and Minoxidil products, and refused to issue a refund until a bank dispute was filed. Users discussed alternative, cheaper sources for these treatments and shared similar negative experiences with Hims.